On August 7, 2023, Nicholas A. LaBella, Jr., Chief Scientific Officer and Senior Vice President of Research and Development at ZyVersa Therapeutics, Inc. (the Company) notified the Company of his planned retirement from the Company effective August 18, 2023. Following his retirement, it is anticipated that Mr. LaBella will become a member of the Company's Scientific Advisory Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.41 USD | -7.16% | -10.73% | -51.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.00% | 3.35M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- ZVSA Stock
- News ZyVersa Therapeutics, Inc.
- ZyVersa Therapeutics, Inc. Announces Board Changes